Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
Objectives Recent studies suggest that implementation of the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis (RA) leads to higher inflammatory activity in seronegative compared with seropositive patients at time...
Published in: | RMD Open |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BMJ Group
2019
|
Subjects: | |
Online Access: | http://hdl.handle.net/10852/71791 http://urn.nb.no/URN:NBN:no-74920 https://doi.org/10.1136/rmdopen-2018-000752 |
id |
ftoslouniv:oai:www.duo.uio.no:10852/71791 |
---|---|
record_format |
openpolar |
spelling |
ftoslouniv:oai:www.duo.uio.no:10852/71791 2023-05-15T14:28:06+02:00 Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial Nordberg, Lena Kristine Bugge Lillegraven, Siri Aga, Anna-Birgitte Sexton, Joseph Inge Christoffer, Olsen Lie, Elisabeth Hammer, Hilde Berner Uhlig, Till Heijde, Desirée van der Kvien, Tore Kristian Haavardsholm, Espen A. 2019-01-22T15:11:18Z http://hdl.handle.net/10852/71791 http://urn.nb.no/URN:NBN:no-74920 https://doi.org/10.1136/rmdopen-2018-000752 EN eng BMJ Group http://urn.nb.no/URN:NBN:no-74920 Nordberg, Lena Kristine Bugge Lillegraven, Siri Aga, Anna-Birgitte Sexton, Joseph Inge Christoffer, Olsen Lie, Elisabeth Hammer, Hilde Berner Uhlig, Till Heijde, Desirée van der Kvien, Tore Kristian Haavardsholm, Espen A. . Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. RMD Open. 2018, 4(2), 11-17 http://hdl.handle.net/10852/71791 1663139 info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=RMD Open&rft.volume=4&rft.spage=11&rft.date=2018 RMD Open 4 2 11 17 https://doi.org/10.1136/rmdopen-2018-000752 URN:NBN:no-74920 Fulltext https://www.duo.uio.no/bitstream/handle/10852/71791/1/Comparing%2Bthe%2Bdisease%2Bcourse%2Bof%2Bpatients%2Bwith%2Bseronegative%2Band%2Bseropositive.pdf Attribution-NonCommercial 4.0 International https://creativecommons.org/licenses/by-nc/4.0/ CC-BY-NC 2056-5933 Journal article Tidsskriftartikkel Peer reviewed PublishedVersion 2019 ftoslouniv https://doi.org/10.1136/rmdopen-2018-000752 2020-06-21T08:52:58Z Objectives Recent studies suggest that implementation of the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis (RA) leads to higher inflammatory activity in seronegative compared with seropositive patients at time of diagnosis. Our aim was to compare the disease course in seronegative and seropositive patients classified according to the 2010 criteria. Methods DMARD-naïve patients with RA fulfilling the 2010 criteria were included in the treat-to-target ARCTIC trial and followed for 24 months. We stratified patients as seropositive (rheumatoid factor (RF)+, anticitrullinated protein antibodies (ACPA)+ or both) or seronegative (RF– and ACPA–) and compared disease activity, radiographic progression, treatment response and remission rates across groups. Results 230 patients were included with mean (SD) age 51.4 (13.7) years, and 61% were female. 34 patients (15%) were seronegative. At 24 months, disease activity measures, radiographic progression and remission rates were similar between groups, despite more inflammatory activity in seronegative patients at baseline. Treatment response was slower in seronegative compared with seropositive patients. The groups received similar treatment. Conclusion Our findings suggest that among patients with RA classified according to the 2010 ACR/EULAR criteria, seronegative patients respond well to modern treatment strategies. However, treatment response was somewhat slower in seronegative patients and radiographic progression was similar in seronegative and seropositive patients. Our results indicate that seronegative RA is not a mild form of the disease and requires intensive treat-to-target therapy similar to treatment of seropositive RA. Article in Journal/Newspaper Arctic Arctic Universitet i Oslo: Digitale utgivelser ved UiO (DUO) Arctic RMD Open 4 2 e000752 |
institution |
Open Polar |
collection |
Universitet i Oslo: Digitale utgivelser ved UiO (DUO) |
op_collection_id |
ftoslouniv |
language |
English |
description |
Objectives Recent studies suggest that implementation of the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis (RA) leads to higher inflammatory activity in seronegative compared with seropositive patients at time of diagnosis. Our aim was to compare the disease course in seronegative and seropositive patients classified according to the 2010 criteria. Methods DMARD-naïve patients with RA fulfilling the 2010 criteria were included in the treat-to-target ARCTIC trial and followed for 24 months. We stratified patients as seropositive (rheumatoid factor (RF)+, anticitrullinated protein antibodies (ACPA)+ or both) or seronegative (RF– and ACPA–) and compared disease activity, radiographic progression, treatment response and remission rates across groups. Results 230 patients were included with mean (SD) age 51.4 (13.7) years, and 61% were female. 34 patients (15%) were seronegative. At 24 months, disease activity measures, radiographic progression and remission rates were similar between groups, despite more inflammatory activity in seronegative patients at baseline. Treatment response was slower in seronegative compared with seropositive patients. The groups received similar treatment. Conclusion Our findings suggest that among patients with RA classified according to the 2010 ACR/EULAR criteria, seronegative patients respond well to modern treatment strategies. However, treatment response was somewhat slower in seronegative patients and radiographic progression was similar in seronegative and seropositive patients. Our results indicate that seronegative RA is not a mild form of the disease and requires intensive treat-to-target therapy similar to treatment of seropositive RA. |
format |
Article in Journal/Newspaper |
author |
Nordberg, Lena Kristine Bugge Lillegraven, Siri Aga, Anna-Birgitte Sexton, Joseph Inge Christoffer, Olsen Lie, Elisabeth Hammer, Hilde Berner Uhlig, Till Heijde, Desirée van der Kvien, Tore Kristian Haavardsholm, Espen A. |
spellingShingle |
Nordberg, Lena Kristine Bugge Lillegraven, Siri Aga, Anna-Birgitte Sexton, Joseph Inge Christoffer, Olsen Lie, Elisabeth Hammer, Hilde Berner Uhlig, Till Heijde, Desirée van der Kvien, Tore Kristian Haavardsholm, Espen A. Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial |
author_facet |
Nordberg, Lena Kristine Bugge Lillegraven, Siri Aga, Anna-Birgitte Sexton, Joseph Inge Christoffer, Olsen Lie, Elisabeth Hammer, Hilde Berner Uhlig, Till Heijde, Desirée van der Kvien, Tore Kristian Haavardsholm, Espen A. |
author_sort |
Nordberg, Lena Kristine Bugge |
title |
Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial |
title_short |
Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial |
title_full |
Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial |
title_fullStr |
Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial |
title_full_unstemmed |
Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial |
title_sort |
comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 acr/eular classification criteria in a treat-to-target setting: 2-year data from the arctic trial |
publisher |
BMJ Group |
publishDate |
2019 |
url |
http://hdl.handle.net/10852/71791 http://urn.nb.no/URN:NBN:no-74920 https://doi.org/10.1136/rmdopen-2018-000752 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic Arctic |
genre_facet |
Arctic Arctic |
op_source |
2056-5933 |
op_relation |
http://urn.nb.no/URN:NBN:no-74920 Nordberg, Lena Kristine Bugge Lillegraven, Siri Aga, Anna-Birgitte Sexton, Joseph Inge Christoffer, Olsen Lie, Elisabeth Hammer, Hilde Berner Uhlig, Till Heijde, Desirée van der Kvien, Tore Kristian Haavardsholm, Espen A. . Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. RMD Open. 2018, 4(2), 11-17 http://hdl.handle.net/10852/71791 1663139 info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=RMD Open&rft.volume=4&rft.spage=11&rft.date=2018 RMD Open 4 2 11 17 https://doi.org/10.1136/rmdopen-2018-000752 URN:NBN:no-74920 Fulltext https://www.duo.uio.no/bitstream/handle/10852/71791/1/Comparing%2Bthe%2Bdisease%2Bcourse%2Bof%2Bpatients%2Bwith%2Bseronegative%2Band%2Bseropositive.pdf |
op_rights |
Attribution-NonCommercial 4.0 International https://creativecommons.org/licenses/by-nc/4.0/ |
op_rightsnorm |
CC-BY-NC |
op_doi |
https://doi.org/10.1136/rmdopen-2018-000752 |
container_title |
RMD Open |
container_volume |
4 |
container_issue |
2 |
container_start_page |
e000752 |
_version_ |
1766302241448263680 |